| Title |
Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, December 2019
|
| DOI | 10.1158/1535-7163.mct-18-1399 |
| Pubmed ID | |
| Authors |
Paulo Bergerot, Peter Lamb, Evelyn Wang, Sumanta K Pal |
X Demographics
The data shown below were collected from the profiles of 84 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 34 | 40% |
| Australia | 4 | 5% |
| Spain | 4 | 5% |
| Brazil | 3 | 4% |
| Switzerland | 2 | 2% |
| Saudi Arabia | 1 | 1% |
| Ecuador | 1 | 1% |
| Germany | 1 | 1% |
| Argentina | 1 | 1% |
| Other | 6 | 7% |
| Unknown | 27 | 32% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 47 | 56% |
| Scientists | 20 | 24% |
| Practitioners (doctors, other healthcare professionals) | 14 | 17% |
| Science communicators (journalists, bloggers, editors) | 3 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 53 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 21% |
| Other | 6 | 11% |
| Student > Doctoral Student | 3 | 6% |
| Student > Bachelor | 3 | 6% |
| Student > Postgraduate | 3 | 6% |
| Other | 7 | 13% |
| Unknown | 20 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 25% |
| Biochemistry, Genetics and Molecular Biology | 4 | 8% |
| Agricultural and Biological Sciences | 4 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Chemical Engineering | 1 | 2% |
| Other | 5 | 9% |
| Unknown | 23 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 52. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2024.
All research outputs
#821,751
of 25,651,057 outputs
Outputs from Molecular Cancer Therapeutics
#87
of 4,083 outputs
Outputs of similar age
#19,691
of 479,092 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#2
of 92 outputs
Altmetric has tracked 25,651,057 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,083 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 479,092 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 92 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.